KATHLEEN MCCLANAHAN: Open Payments
NPI 1275503633 · HOLLYWOOD, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$228 in 11 payments from 7 companies in 2025. Trend: 2023 $258 · 2024 $355 · 2025 $228
Food & beverage: $228
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 4 | $78 |
| Merck Sharp & Dohme LLC | 2 | $44 |
| AstraZeneca Pharmaceuticals LP | 1 | $25 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $25 |
| Boston Scientific Corporation | 1 | $21 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $18 |
| Novartis Pharmaceuticals Corporation | 1 | $17 |
Products named: ELIQUIS, VERQUVO, FARXIGA, JARDIANCE, CDS - MCT/CEM Monitoring, CAMZYOS, Kerendia, LEQVIO.
Industry payments across MD — which companies pay providers there.
